OMEROS CORP Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
OMEROS CORP (OMER) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$1.90 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2023-03-13
- OMEROS CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$1.90M.
- OMEROS CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was -$19.30M, a 151.06% decline from fiscal 2020.
- OMEROS CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $37.80M, a 58.16% increase from fiscal 2019.
- OMEROS CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was $23.90M, a 9.47% decline from fiscal 2018.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2022-12-31 | -$1.90M 10-K · filed 2023-03-13 | |
| 2021-12-31 | -$19.30M 10-K · filed 2023-03-13 | |
| 2020-12-31 | $37.80M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $23.90M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $26.40M 10-K · filed 2020-03-02 | -$26.40M 10-K · filed 2019-03-01 |
| 2017-12-31 | -$32.00M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $24.90M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $30.40M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $25.80M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $14.50M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $13.60M 10-K · filed 2015-03-16 | |
| 2011-12-31 | $9.50M 10-K · filed 2014-03-13 | |
| 2010-12-31 | $11.10M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |